Meitheal Pharmaceuticals gains exclusive U.S. commercial rights to Humira biosimilar
Meitheal, a biopharmaceutical company focused on developing and commercializing generic injectables, fertility, biologic and branded products, has gained exclusive U.S. commercial rights to Yusimry, a biosimilar of Humira.
Through this exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co. Meitheal gains exclusive U.S. rights to Yusimry and responsibility for all commercial activities nationally.
HKF has acquired worldwide rights to Yusimry through an asset purchase agreement with Coherus BioSciences, Inc. for $40 million in cash.
[Read more: PBM rebate schemes to suppress biosimilar Humira cost patients $6B, IQVIA analysis finds]
Yusimry is currently approved by the Food and Drug Administration for nine indications and is available at a lower cost compared to Humira; Meitheal expects additional indications, including a high-concentration formulation, to be approved in 2025.
Yusimry is Meitheal’s fifth biosimilar and its first on-market biosimilar. Meitheal and HKF continue to invest in Meitheal’s biologics portfolio and capabilities, including developing a $30 million monoclonal antibody drug substance facility.
Meitheal said it will work with Coherus to ensure a seamless transition of existing Yumisry operations, including the well-established, comprehensive support hub for patients and healthcare providers.